NASDAQ · Biotechnology · USD

Pulmatrix, Inc. (PULM) Stock Analysis

Pulmatrix, Inc. (PULM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PULM

$1.57

+$0.14 (+9.79%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PULM with… →

PULM Key Statistics

As of Oct 21, 2026

Trading

Open: $1.40
Previous Close: $1.43
Day's Range: 1.38–1.60
52-Week Range: 1.16–4.99
Volume: 113.68K
Beta: 1.93

Valuation

Market Cap: $5.73M
P/E Ratio: unprofitable
EPS (ttm): −1.10

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$5.16M
Shares Outstanding: 3.65M
1-Year Return: −68.23%

Dividend and dates

Avg Volume: 24.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PULM closed at $1.57, −68.23% over 1 year.

Pulmatrix, Inc. (PULM) has a market capitalization of $5.73M.

In fiscal 2025, PULM reported revenue of $0.00.

PULM Stock Return by Calendar Year

Pulmatrix, Inc. (PULM) 10-year return: what $10,000 became

1 year: $10,000 $3,177; −68.23%
5 years: $10,000 $1,084; −89.16%
10 years: $10,000 $58; −99.42%

If you had invested $10,000 in Pulmatrix, Inc. (PULM) 10 years ago, at the close on October 21, 2016, it would have been worth $58 at the close on October 21, 2026: −99.42% in total, −40.28% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−82.98%+275.27%−29.60%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−29.60%
2025	−68.05%
2024	+275.27%
2023	−52.06%
2022	−55.71%
2021	−63.19%
2020	+38.37%
2019	−64.17%
2018	−82.98%
2017	+138.98%
2016 (partial year)	−69.90%

As of October 21, 2026.

PULM Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$5.16M	—
2024	$7.81M	−$9.56M	−122.5%
2023	$7.30M	−$14.12M	−193.5%
2022	$6.07M	−$18.84M	−310.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$5.17M	−$5.16M	—
2024	$7.81M	—	−$7.15M	−$9.56M	−122.5%
2023	$7.30M	—	−$14.74M	−$14.12M	−193.5%
2022	$6.07M	—	−$18.95M	−$18.84M	−310.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pulmatrix, Inc. (PULM) is capitalised at $5.73M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 2 employees.

The 52-week range on file runs from $1.16 to $4.99. The most recent close on file for PULM is $1.57, dated October 21, 2026. That is +$0.14 (+9.79%) against the previous close. The latest close sits 35.34% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $7.81M. The same year closed with a net loss of $5.16M. Trailing earnings per share are −1.1.

Across the 4 fiscal years on file, revenue moves from $6.07M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −68.23%. Across 10 years the annualized return works out at −40.28%. The reported beta is 1.93. Annualized volatility over the trailing 10 years is 111.28%.

Growth & Income

The record shows no dividend for PULM.

So far in 2026 the total return is −29.60%. Across the complete calendar years on file, 2024 returned +275.27% and 2018 returned −82.98%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Pulmatrix, Inc. (PULM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Pulmatrix, Inc.	PULM	$5.73M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Pulmatrix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Pulmatrix, Inc.

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

Visit website →